ATE313559T1 - Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen - Google Patents

Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen

Info

Publication number
ATE313559T1
ATE313559T1 AT00966633T AT00966633T ATE313559T1 AT E313559 T1 ATE313559 T1 AT E313559T1 AT 00966633 T AT00966633 T AT 00966633T AT 00966633 T AT00966633 T AT 00966633T AT E313559 T1 ATE313559 T1 AT E313559T1
Authority
AT
Austria
Prior art keywords
peptide
carrier
hpv
vlp
introducing
Prior art date
Application number
AT00966633T
Other languages
English (en)
Inventor
Per Antonsson
Karin Kristensson
Marie Wallen-Oehman
Joakim Dillner
Peter Lando
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Application granted granted Critical
Publication of ATE313559T1 publication Critical patent/ATE313559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
AT00966633T 1999-09-30 2000-09-19 Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen ATE313559T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903534A SE514982C2 (sv) 1999-09-30 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
PCT/SE2000/001808 WO2001023422A1 (en) 1999-09-30 2000-09-19 Vaccine

Publications (1)

Publication Number Publication Date
ATE313559T1 true ATE313559T1 (de) 2006-01-15

Family

ID=20417209

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00966633T ATE313559T1 (de) 1999-09-30 2000-09-19 Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen

Country Status (25)

Country Link
EP (1) EP1222200B1 (de)
JP (1) JP2003510064A (de)
KR (1) KR20020047195A (de)
CN (1) CN1373771A (de)
AT (1) ATE313559T1 (de)
AU (1) AU771481B2 (de)
BR (1) BR0014666A (de)
CA (1) CA2384723A1 (de)
CZ (1) CZ20021023A3 (de)
DE (1) DE60025016D1 (de)
EE (1) EE200200157A (de)
HR (1) HRP20020092A2 (de)
HU (1) HUP0202770A3 (de)
IL (1) IL148741A0 (de)
MX (1) MXPA02003328A (de)
NO (1) NO20020615L (de)
NZ (1) NZ516725A (de)
PL (1) PL355012A1 (de)
RU (1) RU2002111554A (de)
SE (1) SE514982C2 (de)
SK (1) SK4222002A3 (de)
TR (1) TR200200802T2 (de)
WO (1) WO2001023422A1 (de)
YU (1) YU22202A (de)
ZA (1) ZA200200886B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY139500A (en) * 2003-11-12 2009-10-30 Merck Sharp & Dohme Optimized expression of hpv 58 l1 in yeast
ES2343255T3 (es) * 2004-03-24 2010-07-27 MERCK SHARP & DOHME CORP. Expresion optimizada del vph 52 l1 en levadura.
DE102004036913A1 (de) * 2004-07-16 2006-02-09 Responsif Gmbh Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) * 2004-12-22 2010-04-28 三峡大学 用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) * 2006-03-13 2008-06-04 曾毅 含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) * 2010-07-16 2012-11-21 四川大学 人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
JP2020524710A (ja) 2017-06-23 2020-08-20 パソヴァックス エルエルシー 免疫応答の抗原特異的リダイレクターとしてのキメラウイルス様粒子およびその使用
SG11202106931PA (en) 2018-12-27 2021-07-29 Verimmune Llc Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
CN113454210A (zh) * 2019-02-08 2021-09-28 伦斯勒理工大学 基于精子相关蛋白catsper的避孕疫苗
JP2023552040A (ja) 2020-10-19 2023-12-14 ヴェリミューン インコーポレイテッド ウイルスにインスパイアされた組成物及びがんの治療のために同じものを使用して、既存の免疫応答をリダイレクトする方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2202090C (en) * 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
FR2768749A1 (fr) * 1997-09-22 1999-03-26 Inst Nat Sante Rech Med Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) * 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

Also Published As

Publication number Publication date
RU2002111554A (ru) 2004-03-27
SE9903534D0 (sv) 1999-09-30
KR20020047195A (ko) 2002-06-21
TR200200802T2 (tr) 2002-09-23
NO20020615D0 (no) 2002-02-08
PL355012A1 (en) 2004-03-22
EE200200157A (et) 2003-04-15
BR0014666A (pt) 2002-06-18
NO20020615L (no) 2002-05-29
SE514982C2 (sv) 2001-05-28
CZ20021023A3 (cs) 2002-07-17
AU7695100A (en) 2001-04-30
EP1222200A1 (de) 2002-07-17
SK4222002A3 (en) 2002-10-08
IL148741A0 (en) 2002-09-12
MXPA02003328A (es) 2004-09-10
HUP0202770A3 (en) 2004-07-28
SE9903534L (sv) 2001-03-31
DE60025016D1 (de) 2006-01-26
NZ516725A (en) 2003-03-28
EP1222200B1 (de) 2005-12-21
HRP20020092A2 (en) 2003-06-30
JP2003510064A (ja) 2003-03-18
CA2384723A1 (en) 2001-04-05
ZA200200886B (en) 2003-03-26
AU771481B2 (en) 2004-03-25
CN1373771A (zh) 2002-10-09
YU22202A (sh) 2005-06-10
HUP0202770A2 (hu) 2002-12-28
WO2001023422A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
JP2012010713A (ja) パピローマウイルス様粒子、融合タンパク質並びにそれらの製造方法
ATE313559T1 (de) Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen
DE69731289D1 (de) Immunglobulinähnliche domäne mit erhöhten halbwertszeiten
JPS59500498A (ja) １ａ型乳頭腫ウイルスゲノムのＬ１及びＬ２領域由来のＤＮＡ断片
GB9224584D0 (en) Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
ATE454901T1 (de) Verfahren zur erhaltung zellimmuneantworten gegen proteinen
RU2006131598A (ru) Рекомбинантный белок, несущий эпитопы вируса папилломы человека, встроенные в белок аденилатциклазу или его фрагмент, его терапевтическое применение
BR9913026A (pt) Processo de purificação de partìculas semelhantes a vìrus (vlps) de papilomavìrus recombinante, e, processo de preparação de um produto de vlp de papilomavìrus humano purificado adequado para uso em uma vacina para humano
UY24367A1 (es) Vacunas contra tumores y procedimiento para su produccion
ECSP055635A (es) Agentes citotoxicos que contienen taxanos potentes novedosos y su uso terapeutico
WO2003063801A3 (en) Treatment of tumor cells for use in immunotherapy of cancer
CN106955361B (zh) 一种含有结核病变态反应原ce的药物组合物
KR930702522A (ko) 인체의 투명층 단백질 제트피 3 (zp3)
AR004567A1 (es) Metodos para detectar la infeccion de t.cruzi, en una muestra biologica, un vector de expresion recombinante, un microorganismo modificado, un kit de diagnostico, una composicion farmaceutica, el uso de la composicion farmaceutica para la preparacion de un medicamento para estimular la produccion de anticuerpos que se liguen a t. cruzi.
DK1334197T3 (da) Gær-afledt vaccine mod IPNV
DK1287142T3 (da) Nukleinsyremolekyle omfattende en for et SDF-1 gamma chemokin, en neuropeptid-præcursor eller mindst et neuropeptid kodende nukleinsyresekvens
CN102559725A (zh) 人干细胞生长因子及其聚乙二醇修饰化产物的生产方法及用途
MXPA03007002A (es) Factor estimulante de colonia de granulocitos (g-csf) modificado con inmunogenicidad reducida.
ATE463566T1 (de) Tumor- und seneszenzsmarker
DE60018605D1 (de) Ing2, ein mit iaps assoziiertes zellzyklusprotein, sowie zusammensetzungen, verfahren und verwendungen
GB0028319D0 (en) Materials and methods relating to fusion proteins for inducing an immune response
FR2603040A1 (fr) Proteine, sequence d'adn, poxvirus, cellules et leur procede de culture, ainsi que les compositions pharmaceutiques les contenant, utiles dans la prevention de la schistosomose
WO2002038174A3 (de) Impfstoffe, die rekombinante hantavirusproteine enthalten, verfahren zu ihrer herstellung und ihre verwendung
ATE206619T1 (de) Komplex aus antigen und zellbestandteil, verfahren zur dessen herstellung und therapeutische verwendungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties